目的:应用蛋白芯片技术筛选并探讨参苈加颗粒对心力衰竭大鼠心肌Neuropilin-2表达的影响。方法:将70只清洁级雄性Wi st ar大鼠随机抽取空白组15只,其余用阿霉素造模,将造模成功大鼠随机分为模型组和治疗组,分别给予参苈加颗粒和生理盐...目的:应用蛋白芯片技术筛选并探讨参苈加颗粒对心力衰竭大鼠心肌Neuropilin-2表达的影响。方法:将70只清洁级雄性Wi st ar大鼠随机抽取空白组15只,其余用阿霉素造模,将造模成功大鼠随机分为模型组和治疗组,分别给予参苈加颗粒和生理盐水灌胃每日1次,28天后取大鼠左心室组织,用于HE染色和蛋白芯片分析。结果:HE染色显示空白组大鼠心肌正常;模型组大鼠心肌纤维增粗、紊乱,间质增生,少量炎症细胞浸润;治疗组大鼠心肌排列较整齐,间质无明显增生,未见炎症细胞浸润。蛋白芯片可见Neuropilin-2存在差异性表达,与空白组相比,Neuropilin-2在模型组的表达下调;与模型组比较,Neuropilin-2在参苈加治疗组的表达上调;其余2组比较无表达差异。结论:参苈加颗粒可通过调节心肌Neuropilin-2的表达改善心肌纤维化和心肌细胞凋亡,对慢性心衰大鼠心脏起保护作用。展开更多
Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be ...Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer（NSCLC） and their clinical significance by observing patient prognosis. Methods： VEGFR2 and NRP-1 were assessed by immunohistochemistry（IHC） in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor（KDR） and NRP-1 copy number gain（CNG） was assessed by fluorescence in situ hybridization（FISH）. The distributions of overall survival（OS） and progression-free survival（PFS） were estimated using the Kaplan-Meier method and compared between groups by log-rank test.Results： Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG（＋） were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue（χ2=11.22, P=0.001; χ2=9.82, P=0.001, respectively）; similar results were obtained using CNGs（χ2=4.39, P=0.036; χ2=3.95, P=0.046, respectively）. Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status（P〈0.05）, but not age, gender or pathology type（P〉0.05）. VEGFR2 showed a strong correlation with NRP-1（Rs=0.68, P=0.00）; similar results were observed with KDR and NRP-1 CNG（Rs=0.32, P=0.04）. Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression（P〈0.05）. Conclusions： According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis（P〈0.05 for OS and PFS）. This information will be beneficial for clinical antiangiogenic treatment in NSCLC.展开更多
文摘目的:应用蛋白芯片技术筛选并探讨参苈加颗粒对心力衰竭大鼠心肌Neuropilin-2表达的影响。方法:将70只清洁级雄性Wi st ar大鼠随机抽取空白组15只,其余用阿霉素造模,将造模成功大鼠随机分为模型组和治疗组,分别给予参苈加颗粒和生理盐水灌胃每日1次,28天后取大鼠左心室组织,用于HE染色和蛋白芯片分析。结果:HE染色显示空白组大鼠心肌正常;模型组大鼠心肌纤维增粗、紊乱,间质增生,少量炎症细胞浸润;治疗组大鼠心肌排列较整齐,间质无明显增生,未见炎症细胞浸润。蛋白芯片可见Neuropilin-2存在差异性表达,与空白组相比,Neuropilin-2在模型组的表达下调;与模型组比较,Neuropilin-2在参苈加治疗组的表达上调;其余2组比较无表达差异。结论:参苈加颗粒可通过调节心肌Neuropilin-2的表达改善心肌纤维化和心肌细胞凋亡,对慢性心衰大鼠心脏起保护作用。
基金supported by National Natural Science Foundation of China [81472792]Ministry of Health of China (W201210)Jiangsu Natural Science Foundation of China (BK2012661)
文摘Objective： Vascular-targeted therapy is gradually becoming more appealing for patients with lung cancer. It is unclear whether vascular endothelial growth factor receptor 2（VEGFR2） and neuropilin-1（NRP-1） can be biomarkers for clinical treatment. We aimed to investigate the expression levels of VEGFR2 and NRP-1 in human non-small cell lung cancer（NSCLC） and their clinical significance by observing patient prognosis. Methods： VEGFR2 and NRP-1 were assessed by immunohistochemistry（IHC） in 40 patients with NSCLC and in 10 patients with benign lesions of lung; kinase insert domain receptor（KDR） and NRP-1 copy number gain（CNG） was assessed by fluorescence in situ hybridization（FISH）. The distributions of overall survival（OS） and progression-free survival（PFS） were estimated using the Kaplan-Meier method and compared between groups by log-rank test.Results： Rates of positive immunostaining for VEGFR2 and NRP-1 were 58% and 55%, respectively. KDR and NRP-1 CNG（＋） were detected in 32.5% and 30% of tumors, respectively. Levels of both VEGFR2 and NRP-1 in lung tumors were significantly different than in the control tissue（χ2=11.22, P=0.001; χ2=9.82, P=0.001, respectively）; similar results were obtained using CNGs（χ2=4.39, P=0.036; χ2=3.95, P=0.046, respectively）. Statistically significant correlations were observed with histological grade, clinical TNM stage and the lymph node status（P〈0.05）, but not age, gender or pathology type（P〉0.05）. VEGFR2 showed a strong correlation with NRP-1（Rs=0.68, P=0.00）; similar results were observed with KDR and NRP-1 CNG（Rs=0.32, P=0.04）. Significant differences in OS and PFS were observed between the groups with higher VEGFR2 and NRP-1 and those with lower expression（P〈0.05）. Conclusions： According to these data, VEGFR2 and NRP-1 are highly expressed in NSCLC. We can conclude that they play a key role in NSCLC occurrence, development and metastasis and are associated with patient prognosis（P〈0.05 for OS and PFS）. This information will be beneficial for clinical antiangiogenic treatment in NSCLC.
